Good afternoon :)
Place Order
Add to Watchlist

Poly Medicure Ltd

POLYMED Share Price

2,122.002.99% (+61.60)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹21,639 cr, stock is ranked 327

Stock is 3.35x as volatile as Nifty

How to use scorecard? Learn more

With a market cap of ₹21,639 cr, stock is ranked 327

Stock is 3.35x as volatile as Nifty

POLYMED Performance & Key Metrics

POLYMED Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
63.9214.720.16%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.656.540.85%

POLYMED Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
60%
Analysts have suggested that investors can buy this stock

from 5 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

POLYMED Company Profile

Poly Medicure Limited is engaged in the manufacturing and sale of medical devices.

POLYMED Similar Stocks (Peers)

Compare with peers Compare with peers 

POLYMED Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
58.58
58.58
1Y Return
14.77%
14.77%
Buy Reco %
25.00
25.00
PE Ratio
70.37
70.37
1Y Return
26.43%
26.43%
Buy Reco %
100.00
100.00
PE Ratio
66.85
66.85
1Y Return
26.79%
26.79%
Buy Reco %
80.00
80.00
PE Ratio
46.69
46.69
1Y Return
16.46%
16.46%
Buy Reco %
0.00
0.00
PE Ratio
31.48
31.48
1Y Return
6.38%
6.38%
Buy Reco %
0.00
0.00
Compare with Peers

POLYMED Sentiment Analysis

POLYMED Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

POLYMED Stock Summary · May 2025

Poly Medicure Limited demonstrated robust financial performance in FY '25, achieving a 21.5% revenue growth driven by a remarkable 60% increase in its Renal business. While the company is strategically shifting focus towards the domestic market, anticipating a 30%-32% growth, it remains cautious about export challenges, particularly in Europe. A significant capital expenditure plan of Rs. 500 crores aims to enhance manufacturing capabilities, supported by a commitment to innovation reflected in 334 global patents. Despite a reduced dividend payout ratio to conserve cash for potential mergers and acquisitions, management emphasizes operational efficiency and market competitiveness, positioning itself for sustainable growth amidst evolving market dynamics.

POLYMED Stock Growth Drivers
POLYMED Stock Growth Drivers
8
  • Strong Financial Performance

    Poly Medicure Limited has reported significant financial achievements, including a consolidated revenue increase from Rs.

  • Successful Product Launches and Innovations

    The company has accelerated its product development, launching approximately 30 new products in FY '25,

POLYMED Stock Challenges
POLYMED Stock Challenges
4
  • Decreasing Government Revenue

    The company has experienced a decline in government revenue, which now constitutes approximately 10% to

  • Poor Margins in Renal Business

    The company is currently facing poor margins in its Renal business due to its early-stage

POLYMED Forecast

POLYMED Forecasts

Price

Revenue

Earnings

POLYMED

POLYMED

Income

Balance Sheet

Cash Flow

POLYMED Income Statement

POLYMED Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 17.91%, vs industry avg of 17.66%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 52.57% to 26.31%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 31.6%, vs industry avg of 3.47%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue468.95536.04630.50707.84808.20963.411,153.341,437.071,764.141,764.13
Raw Materialssubtract119.62176.07165.66178.89214.22296.55345.37382.511,216.991,216.59
Power & Fuel Costsubtract16.7819.0424.7425.6225.2729.8438.5944.29
Employee Costsubtract87.2699.13116.61138.76141.76163.62202.75245.91
Selling & Administrative Expensessubtract47.0845.2458.0561.0356.2066.9777.7895.63
Operating & Other expensessubtract90.8058.98114.53116.82132.53151.07183.34246.97
Depreciation/Amortizationsubtract23.7329.2437.2940.5347.5253.9557.1763.9382.6483.04
Interest & Other Itemssubtract8.4911.5813.5320.4810.646.1610.8613.5612.0012.00
Taxes & Other Itemssubtract20.0626.1634.6729.8544.1848.7458.2186.01113.95113.97
EPS6.258.007.4110.8614.7615.2818.6926.9134.1335.27
DPS2.502.002.002.002.502.503.003.003.503.00
Payout ratio0.400.250.270.180.170.160.160.110.100.09

POLYMED Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

May 24PDF
FY 2021FY 2021

Annual report

PDF

Investor Presentation

May 25PDF
Feb 4PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual report

PDF
 

POLYMED Stock Peers

POLYMED Past Performance & Peer Comparison

POLYMED Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareHealth Care Equipment & Supplies

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Poly Medicure Ltd63.9214.720.16%
Inventurus Knowledge Solutions Ltd58.5824.59
Laxmi Dental Ltd70.3750.18
Tarsons Products Ltd66.853.25

POLYMED Stock Price Comparison

Compare POLYMED with any stock or ETF
Compare POLYMED with any stock or ETF
POLYMED
Loading...

POLYMED Holdings

POLYMED Shareholdings

POLYMED Promoter Holdings Trend

POLYMED Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

POLYMED Institutional Holdings Trend

POLYMED Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

POLYMED Shareholding Pattern

POLYMED Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding62.44%7.16%4.80%11.46%14.15%

Aug 2024

Sep 2024

Dec 2024

Mar 2025

POLYMED Shareholding History

POLYMED Shareholding History

MarJunAugSepDec '24Mar12.38%9.91%11.10%11.87%12.33%11.46%

Mutual Funds Invested in POLYMED

Mutual Funds Invested in POLYMED

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Poly Medicure Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
3.3388%2.56%-0.16%9/112 (-1)
1.4639%1.25%-0.04%43/64 (-3)
0.5287%3.10%-0.22%14/32 (-4)

Compare 3-month MF holding change on Screener

POLYMED Insider Trades & Bulk Stock Deals

POLYMED Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing POLYMED stock

smallcases containing POLYMED stock

Looks like this stock is not in any smallcase yet.

POLYMED Events

POLYMED Events

POLYMED Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

POLYMED has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.16%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.55 every year

Dividends

Corp. Actions

Announcements

Legal Orders

POLYMED Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

POLYMED has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.16%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.55 every year

POLYMED Upcoming Dividends

POLYMED Upcoming Dividends

No upcoming dividends are available

POLYMED Past Dividends

POLYMED Past Dividends

Cash Dividend

Ex DateEx DateSep 19, 2024

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Sep 19, 2024

Cash Dividend

Ex DateEx DateSep 21, 2023

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Sep 21, 2023

Cash Dividend

Ex DateEx DateSep 16, 2022

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 16, 2022

Cash Dividend

Ex DateEx DateSep 16, 2021

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 16, 2021

Cash Dividend

Ex DateEx DateFeb 27, 2020

Interim
Interim | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Feb 27, 2020

POLYMED Stock News & Opinions

POLYMED Stock News & Opinions

Corporate
Board of Poly Medicure recommends final dividend

Poly Medicure announced that the Board of Directors of the Company at its meeting held on 6 May 2025, inter alia, have recommended the final dividend of Rs 3.5 per equity Share (i.e. 70%) , subject to the approval of the shareholders.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Poly Medicure consolidated net profit rises 34.33% in the March 2025 quarter

Net profit of Poly Medicure rose 34.33% to Rs 91.83 crore in the quarter ended March 2025 as against Rs 68.36 crore during the previous quarter ended March 2024. Sales rose 16.60% to Rs 440.83 crore in the quarter ended March 2025 as against Rs 378.07 crore during the previous quarter ended March 2024. For the full year,net profit rose 31.09% to Rs 338.56 crore in the year ended March 2025 as against Rs 258.26 crore during the previous year ended March 2024. Sales rose 21.37% to Rs 1669.83 crore in the year ended March 2025 as against Rs 1375.80 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales440.83378.07 17 1669.831375.80 21 OPM %27.1025.51 -27.1226.00 - PBDT143.88108.54 33 535.15407.71 31 PBT122.8592.46 33 452.52344.27 31 NP91.8368.36 34 338.56258.26 31 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Poly Medicure to announce Quarterly Result

Poly Medicure will hold a meeting of the Board of Directors of the Company on 6 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Poly Medicure incorporates wholly owned subsidiary - Polyhealth

Poly Medicure has incorporated a wholly owned Step down subsidiary named Polyhealth in England and Wales on 04 February 2025. Polyhealth will be engaged in maufacturing and distribution of Medical Devices with great experiences for its customers. The focus will be on the supply chain and cater the Medical Devices market and/or any other activities ancillary and incidental thereto in in England and wales and other parts of Europe also. Powered by Capital Market - Live

4 months agoCapital Market - Live
Spotlight
Poly Medicure spurts as PAT climbs 31% YoY to Rs 85 crore in Q3

The revenue growth was driven by the firm's robust market presence and effective growth strategies. Profit before tax increased 28.93% year on year (YoY) to Rs 113.23 crore in the quarter ended 31 December 2023. EBITDA grew 27.9% YoY to Rs 116.3 crore during the quarter. EBITDA margin improved to 27.4% in Q3 FY25, compared to 26.8% posted in Q3 FY24. Total expenses in Q3 FY25 were at Rs 334.51 crore, up 24.33% YoY. Cost of materials consumed was Rs 141.95 crore (up 19.57% YoY) while employee benefits expense stood at Rs 77.89 crore (up 28.96% YoY) during the period under review. On nine-month basis, the company's consolidated net profit climbed 29.92% to Rs 246.72 crore on 23.18% rise in revenue to Rs 1,229 crore in Q3 FY25 over Q3 FY24. Export revenue for the nine months increased by 29% YoY, driven by continued strong performance in key international markets. The domestic quarterly and nine-month revenue growth of 24% and 17% YoY respectively on a YoY basis, demonstrating the company's continued investments in building R&D and sales capabilities. Himanshu Baid, managing director, Poly Medicure stated: 'We are extremely pleased with our continued growth in the business in the last quarter. Overall revenue grew by almost 25% with EBITDA and PAT growing by 28% and 31% respectively. We are on track to achieve our revenue growth guidance of 22-24% while improving our EBITDA margin by 100 ' 150 bps. I am very excited to share that we have received regulatory approval to launch our Drug Eluting Stent and commercialisation of that is expected soon. That will give a significant fillip to our Cardiology business. We continue to invest aggressively in building our manufacturing capacities and recently ground-breaking ceremony was held at our Palwal Plant, which will be the largest plant that we would be seƫng up at a single location. We have also signed a JV agreement to set up a 10MW Solar Power plant in Haryana where we will own 26% stake. This will go a long way in achieving our sustainability goals and reduce our carbon-footprint. We are very excited about the growth opportunity that India provides in the MedTech sector and our continued investments strongly reflects in that belief.' Poly Medicure exports plastic medical disposables/surgical devices. It manufactures and supplies approximately 100 types of disposable medical devices in the product verticals of infusion therapy, anesthesia, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis and central venous access catheters. Powered by Capital Market - Live

4 months agoCapital Market - Live
Spotlight
Poly Medicure Ltd leads gainers in 'A' group

NLC India Ltd, Prudent Corporate Advisory Services Ltd, Redtape Ltd and Nuvama Wealth Management Ltd are among the other gainers in the BSE's 'A' group today, 04 February 2025.Poly Medicure Ltd soared 10.29% to Rs 2518.55 at 11:48 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 9522 shares were traded on the counter so far as against the average daily volumes of 6553 shares in the past one month. NLC India Ltd surged 10.25% to Rs 232.9. The stock was the second biggest gainer in 'A' group. On the BSE, 7.94 lakh shares were traded on the counter so far as against the average daily volumes of 75652 shares in the past one month. Prudent Corporate Advisory Services Ltd spiked 9.42% to Rs 2199.3. The stock was the third biggest gainer in 'A' group. On the BSE, 4479 shares were traded on the counter so far as against the average daily volumes of 3548 shares in the past one month. Redtape Ltd jumped 9.39% to Rs 198. The stock was the fourth biggest gainer in 'A' group. On the BSE, 52286 shares were traded on the counter so far as against the average daily volumes of 9962 shares in the past one month. Nuvama Wealth Management Ltd gained 8.70% to Rs 5551.05. The stock was the fifth biggest gainer in 'A' group. On the BSE, 7669 shares were traded on the counter so far as against the average daily volumes of 7409 shares in the past one month. Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Poly Medicure consolidated net profit rises 31.08% in the December 2024 quarter

Net profit of Poly Medicure rose 31.08% to Rs 85.23 crore in the quarter ended December 2024 as against Rs 65.02 crore during the previous quarter ended December 2023. Sales rose 24.91% to Rs 424.21 crore in the quarter ended December 2024 as against Rs 339.60 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales424.21339.60 25 OPM %27.0026.57 - PBDT134.74104.04 30 PBT113.2387.82 29 NP85.2365.02 31 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Poly Medicure to discuss results

Poly Medicure will hold a meeting of the Board of Directors of the Company on 3 February 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Poly Medicure enters into JV agreement with AMPIN C&I Power

Poly Medicure has entered into a joint venture agreement with AMPIN C&I Power for the purpose of setting up a Solar Power Project, which will be set up to supply power to the Company as a captive generating plant for Company's manufacturing facility, in Haryana, India. Pursuant to the said JV Agreement, the proposed JV Company will be 26% owned by Poly Medicure and 74% owned by AMPIN C&I Power. Powered by Capital Market - Live

5 months agoCapital Market - Live
Spotlight
Poly Medicure Ltd leads losers in 'A' group

Adani Green Energy Ltd, DCM Shriram Ltd, Fortis Healthcare Ltd and Emami Ltd are among the other losers in the BSE's 'A' group today, 26 November 2024.Poly Medicure Ltd tumbled 7.27% to Rs 2784.4 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 21486 shares were traded on the counter so far as against the average daily volumes of 14968 shares in the past one month.Adani Green Energy Ltd lost 6.47% to Rs 905. The stock was the second biggest loser in 'A' group.On the BSE, 3.82 lakh shares were traded on the counter so far as against the average daily volumes of 2.73 lakh shares in the past one month.DCM Shriram Ltd crashed 5.49% to Rs 1159.95. The stock was the third biggest loser in 'A' group.On the BSE, 19312 shares were traded on the counter so far as against the average daily volumes of 15940 shares in the past one month.Fortis Healthcare Ltd plummeted 4.92% to Rs 666.25. The stock was the fourth biggest loser in 'A' group.On the BSE, 49929 shares were traded on the counter so far as against the average daily volumes of 46145 shares in the past one month.Emami Ltd corrected 4.27% to Rs 663.45. The stock was the fifth biggest loser in 'A' group.On the BSE, 18549 shares were traded on the counter so far as against the average daily volumes of 17507 shares in the past one month.Powered by Capital Market - Live

6 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Poly Medicure Ltd (POLYMED) today?

    The share price of POLYMED as on 23rd June 2025 is ₹2122. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Poly Medicure Ltd (POLYMED) share?

    The past returns of Poly Medicure Ltd (POLYMED) share are
    • Past 1 week: -7.01%
    • Past 1 month: -16.28%
    • Past 3 months: -8.11%
    • Past 6 months: -20.62%
    • Past 1 year: 2.96%
    • Past 3 years: 208.56%
    • Past 5 years: 593.62%

  3. What are the peers or stocks similar to Poly Medicure Ltd (POLYMED)?
  4. What is the dividend yield % of Poly Medicure Ltd (POLYMED) share?

    The current dividend yield of Poly Medicure Ltd (POLYMED) is 0.16.

  5. What is the market cap of Poly Medicure Ltd (POLYMED) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Poly Medicure Ltd (POLYMED) is ₹21639.12 Cr as of 23rd June 2025.

  6. What is the 52 week high and low of Poly Medicure Ltd (POLYMED) share?

    The 52-week high of Poly Medicure Ltd (POLYMED) is ₹3357.80 and the 52-week low is ₹1810.15.

  7. What is the PE and PB ratio of Poly Medicure Ltd (POLYMED) stock?

    The P/E (price-to-earnings) ratio of Poly Medicure Ltd (POLYMED) is 63.92. The P/B (price-to-book) ratio is 14.72.

  8. Which sector does Poly Medicure Ltd (POLYMED) belong to?

    Poly Medicure Ltd (POLYMED) belongs to the Health Care sector & Health Care Equipment & Supplies sub-sector.

  9. How to buy Poly Medicure Ltd (POLYMED) shares?

    You can directly buy Poly Medicure Ltd (POLYMED) shares on Tickertape. Simply sign up, connect your demat account and place your order.